Other Information (please complete)

Patient's Name:

.....

Doctor's Name:

.....

Doctor's Phone:

.....

This card and its content have been approved by the Ministry of Health in February 2025.

Version 1.0

Pfizer Pharmaceuticals Israel Ltd.
9 Shenkar St. Herzliya Pituach, Israel.
Tel: 09-9700500, Fax: 09-9700501

Velsipity
(etrasimod)

Pregnancy-Specific Patient Card

Patient information

If used during pregnancy, Velsipity can harm the unborn baby. Potential risks include loss of the unborn baby and birth defects.

- Do not use Velsipity if you are pregnant or breastfeeding or could become pregnant and are not using effective contraception.
- Before starting treatment with Velsipity:
  1. Your prescriber will explain the potential risks to an unborn baby if you become pregnant while taking Velsipity and will regularly inform you how to minimise the risks.
  2. You must use effective contraception while taking Velsipity and at least 14 days after you stop taking Velsipity.

  3. Your doctor will carry out a pregnancy test and it must be negative. Pregnancy tests will also be checked during treatment.
- Tell your doctor immediately if you become pregnant during treatment with Velsipity or for at least 14 days after you stop taking it. Your doctor will discuss the risk of harmful effects to the baby associated with treatment and may arrange further tests such as an ultrasound. Velsipity must be stopped during pregnancy.
- Tell your doctor right away if you are pregnant or breastfeeding, think you might be pregnant or are planning to have a baby.
- Keep this card with you and show it to any doctor or pharmacist involved in your care.

- See the Velsipity package leaflet for more information.

Reporting side effects

It is important that any side effects should be reported, even those not listed in the patient information leaflet.

Side effects can be reported directly to the Ministry of Health using the adverse events reporting portal which is available on the home page of the Ministry of Health website:
http://www.health.gov.il

or by this link:
https://sideeffects.health.gov.il

Side effects can also be reported to Pfizer by email:
isr.aereporting@pfizer.com